Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584990 | 0.86 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1ADRA2CKDM4EHTR3E | |
| SCHEMBL1901740 | 0.83 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1KDM4EMAPTGAA | |
| SCHEMBL1899796 | 0.81 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KDM4EMAPTGAA | |
| SCHEMBL1899800 | 0.81 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KDM4EMAPTGAA | |
| SCHEMBL1903286 | 0.81 | GAA (0.47) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL188362 | 0.80 | ADRA2C (0.42) | ALDH1A1L3MBTL1ADRA2CKDM4EHTR3E | |
| SCHEMBL4113163 | 0.80 | DRD2 (0.51) | ALDH1A1L3MBTL1ADRA2CKDM4EHTR3E | |
| SCHEMBL25220513 | 0.79 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1KDM4EMAPTMAPK1 | |
| SCHEMBL8213975 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KDM4EMAPTGAA | |
| SCHEMBL20521347 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HTR3ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109851602-B | 14-deoxy-11,12-dehydro-8,12-epoxy-andrographolide and 15-substituted derivatives thereof | 郑州大学 | 2023-04-11 | — | — | CN | claimed |
| US-11591329-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | claimed |
| US-11369584-B2 | Andrographolide derivatives and method of using the same for treatment or prevention of fibrosis | ZHENGZHOU UNIVERSITY (CN) | 2022-06-28 | — | — | US | claimed |
| CN-109771416-B | Application of 14-deoxy-11, 12-dehydro-7, 8-ene-andrographolide and 15-subunit substituted derivative | 郑州大学 | 2021-05-11 | — | — | CN | claimed |
| US-20210047307-A1 | ANDROGRAPHOLIDE COMPOUND AND METHOD FOR TREATMENT OR PREVENTION OF FIBROTIC DISEASE USING THE SAME | ZHENGZHOU UNIVERSITY (CN) | 2021-02-18 | — | — | US | claimed |
| WO-2021007269-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-01-14 | — | — | WO | claimed |
| US-20210009582-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-01-14 | — | — | US | claimed |
| EP-3608313-A1 | 15-IDENE-14-DEOXY-11,12-DEHYDROANDROGRAPHOLIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARING ANTI-FIBROSIS DRUGS | Zhengzhou University (CN) | 2020-02-12 | — | — | EP | claimed |
| US-20200030280-A1 | ANDROGRAPHOLIDE DERIVATIVES AND METHOD OF USING THE SAME FOR TREATMENT OR PREVENTION OF FIBROSIS | ZHENGZHOU UNIVERSITY (CN) | 2020-01-30 | — | — | US | claimed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | claimed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | claimed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | claimed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-109851602-B | 14-deoxy-11,12-dehydro-8,12-epoxy-andrographolide and 15-substituted derivatives thereof | 郑州大学 | 2023-04-11 | — | — | CN | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030280-A1 | ANDROGRAPHOLIDE DERIVATIVES AND METHOD OF USING THE SAME FOR TREATMENT OR PREVENTION OF FIBROSIS | MMP1, CYP27A1, PYGL | ALDH1A1 356/4885L3MBTL1 4551/4885ADRA2C 3840/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | ALDH1A1 865/4885L3MBTL1 279/4885ADRA2C 4018/4885 |
| US-11591329-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ALDH1A1 802/4885L3MBTL1 3560/4885ADRA2C 4397/4885 |
| US-20210047307-A1 | ANDROGRAPHOLIDE COMPOUND AND METHOD FOR TREATMENT OR PREVENTION OF FIBROTIC DISEASE USING THE SAME | NR3C2, COL2A1, FIBP | ALDH1A1 2625/4885L3MBTL1 1059/4885ADRA2C 1489/4885 |
| US-20210009582-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | ALDH1A1 802/4885L3MBTL1 3560/4885ADRA2C 4397/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | ALDH1A1 433/4885L3MBTL1 4067/4885ADRA2C 1600/4885 |
| US-11369584-B2 | Andrographolide derivatives and method of using the same for treatment or prevention of fibrosis | MMP1, CYP27A1, PYGL | ALDH1A1 356/4885L3MBTL1 4551/4885ADRA2C 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.